TR

Trajan Group Holdings Ltd

TRJ · AU · Healthcare / Medical Instruments & Supplies

0.26AUD-0.01 (-1.89%)

Price History

Full chart

Market Stats

Previous Close0.265
Open0.265
Day Range0.26 – 0.265
52-Week Range0.145 – 0.865
Volume10.00K
Market Cap39.74M
P/E (TTM)0.00
Forward P/E20.00
EPS0.00
Dividend Yield0.00%
Beta0.44
50-Day Avg0.1989
200-Day Avg0.3829

About

Trajan Group Holdings Limited develops and manufactures analytical and life science products and devices in Malaysia, Japan, Australia, New Zealand, the United States, Europe, the Middle East, Africa, and India. The company offers analytical products, including gas purifiers and filters, inlet liners, syringes, CB emitters, and tubing products, as well as columns, connections, septa, and inlet liners. It also provides sampling products comprising septa, caps, liners, well plates and sealing mats, crimping tools, and micro-sampling tools. In addition, the company provides pathology products, such as NBF containers; adhesive and frosted microscope slides; coverslips; microtome blades; biopsy pads; tissue marking dyes and sets; microscope slide storage trays/mailers; microscope slide and cassette storage boxes; and histology wax plus. Further, it offers analytical, automation, life sciences, sampling literature support products. The company was incorporated in 2011 and is headquartered in Ringwood, Australia.

Company Details

  • SectorHealthcare
  • IndustryMedical Instruments & Supplies
  • CEOMr. Stephen Tomisich
  • Employees620
  • Headquarters7 Argent Place, Ringwood, VIC, Australia, 3134, Australia
  • Websitehttps://www.trajanscimed.com

Leadership

  • Mr. Stephen TomisichFounder, CEO, MD & Executive Director
  • Mr. Simon BillinghamInterim CFO & Interim Joint Company Secretary
  • Mr. Robert LyonExecutive Director, Head of Corporate Development & General Counsel
  • Mr. Nigel GilliganChief Operations Officer
  • Dr. Andrew Arthur Gooley FCA, MAICD, Ph.D.Chief Scientific Officer
  • Ms. Marie KrsticHead of Corporate Communications & Investor Relations
  • Mr. Mark Andrew Licciardo B Bus (Acc), FCIS, FGIA, GAICD, GradDip CSPJoint Company Secretary · b. 1964
  • Ms. Rebecca Jayne Wilson B.A.Investor Relations Advisor · b. 1973

Financials

Income Statement

Currency: AUD2017-06-302018-06-302019-06-302020-06-302021-06-302022-06-302023-06-302024-06-302025-06-302026-06-30
Total Revenue54.29M57.19M67.77M71.85M76.57M107.57M162.15M155.02M166.46M161.38M
Growth (%)-+5.34%+18.49%+6.03%+6.56%+40.49%+50.74%-4.40%+7.38%-3.05%
Cost of Revenue30.02M49.69M60.07M65.99M48.08M64.94M139.23M95.27M102.99M144.52M
Gross Profit24.27M7.50M7.69M5.86M28.48M42.63M22.93M59.75M63.47M16.86M
Gross Margin44.70%13.12%11.35%8.16%37.20%39.63%14.14%38.55%38.13%10.45%
Operating Expense24.02M5.06M4.73M4.44M26.41M39.72M12.72M56.37M59.99M12.62M
Operating Income243.00K2.44M2.96M1.43M2.08M2.91M10.21M3.39M3.48M4.24M
Operating Margin0.45%4.27%4.37%1.98%2.71%2.71%6.29%2.18%2.09%2.63%
EBITDA1.09M3.16M4.45M3.26M3.46M5.14M14.16M-20.36M8.14M12.96M
EBITDA Margin2.01%5.52%6.57%4.54%4.52%4.78%8.73%-13.13%4.89%8.03%
Net Income691.00K1.45M2.14M2.62M1.88M1.70M1.89M-25.33M-4.46M-623.00K
Net Income Margin1.27%2.53%3.16%3.65%2.46%1.58%1.16%-16.34%-2.68%-0.39%
R&D-------6.22M--
R&D as % of Total Revenue-------4.01%--
Interest Expense0558.00K617.00K612.00K509.00K1.26M4.02M4.54M3.53M3.94M
Interest Expense % of Total Revenue0.00%0.98%0.91%0.85%0.66%1.18%2.48%2.93%2.12%2.44%

Balance Sheet

Currency: AUD2017-06-302018-06-302019-06-302020-06-302021-06-302022-06-302023-06-302024-06-302025-06-302026-06-30
Total Assets30.67M33.02M41.37M44.37M99.38M206.78M229.04M188.00M195.63M183.94M
Total Liabilities19.27M19.39M25.35M26.63M33.30M90.27M99.51M85.15M90.01M85.47M
Total Equity11.39M13.63M16.02M17.74M66.08M116.51M129.53M102.85M105.62M98.47M
Cash2.34M3.55M3.98M4.79M51.72M13.16M11.04M11.24M11.85M12.62M
Total Debt9.18M9.12M9.51M14.97M17.02M66.18M61.30M56.16M55.49M57.95M
Net Debt6.84M5.57M4.50M10.19M-34.70M53.02M50.27M44.92M43.64M45.33M

Cash Flow

Currency: AUD2017-06-302018-06-302019-06-302020-06-302021-06-302022-06-302023-06-302024-06-302025-06-302026-06-30
Operating Cash Flow2.11M1.69M2.84M1.76M9.86M2.74M9.55M9.47M10.83M242.00K
Investing Cash Flow-1.80M-618.00K-3.06M-797.00K402.00K-116.38M-8.55M-3.04M-4.09M-3.42M
Financing Cash Flow-4.00K-60.00K396.00K-236.00K36.81M74.69M-3.36M-6.40M-5.64M3.36M
Capital Expenditure1.80M618.00K2.67M797.00K1.11M3.42M8.55M3.04M4.09M3.42M
Free Cash Flow310.00K1.08M164.00K964.00K-1.11M-3.42M998.00K6.43M6.74M-3.17M
Dividends Paid-3.35M3.35M3.35M3.35M49.22M181.00K---
FCF to OCF14.71%63.52%5.78%54.74%-11.22%-124.73%10.45%67.92%62.26%-1311.98%
Dividend Paid to FCF-311.34%2042.68%347.51%-302.89%-1441.14%18.14%---

Earnings

Report DateJun 3, 2021Aug 24, 2021Feb 23, 2022Aug 23, 2022Feb 26, 2023Feb 26, 2025Aug 27, 2025
EPS Estimate0.000.000.000.000.000.000.00
EPS Actual0.02-0.010.000.010.02-0.02-0.01
Surprise-------
Timing-------

Key Statistics & Ratios

Market Cap39.74M
Enterprise Value86.76M
Trailing P/E0.00
Forward P/E20.00
Price / Sales0.25
Price / Book0.42
EPS0.00
Book Value0.676
Revenue (TTM)161.38M
Gross Profit (TTM)59.95M
EBITDA9.29M
Profit Margin-0.39%
Operating Margin2.58%
Return on Equity-0.61%
Return on Assets1.00%
Shares Outstanding152.86M
Shares Float62.56M
Beta0.44
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%